ADMA (ADMA Biologics) Total Liabilities: $274.9 Mil (As of Mar. 2026)

What is ADMA Biologics Total Liabilities?

ADMA Biologics ADMA +0.34% 64 Total Liabilities is $274.9 Mil as of Mar. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $17.95 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ADMA Biologics's Total Liabilities for the quarter that ended in Mar. 2026 was $274.9 Mil.

ADMA Biologics's quarterly Total Liabilities increased from Sep. 2025 ($137.50 Mil) to Dec. 2025 ($146.92 Mil) and increased from Dec. 2025 ($146.92 Mil) to Mar. 2026 ($274.86 Mil).

ADMA Biologics's annual Total Liabilities declined from Dec. 2023 ($193.98 Mil) to Dec. 2024 ($139.66 Mil) but then increased from Dec. 2024 ($139.66 Mil) to Dec. 2025 ($146.92 Mil).

ADMA Biologics Total Liabilities Related Terms

ADMA Biologics Total Liabilities Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Total Liabilities Chart

ADMA Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

135.08

196.49

193.98

139.66

146.92

ADMA Biologics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															137.15	160.06	137.50	146.92	274.86

64GF Score

ADMA Biologics Inc ADMA

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ADMA Biologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ADMA Biologics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	69.541	+	(75.976	+	1.1102230246252E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	1.405	+	0	+	0)
	=	146.9

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	624.242	-	477.32
	=	146.9

ADMA Biologics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	73.541	+	(199.949	+	-2.8643754035329E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	1.369	+	0	+	0)
	=	274.9

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	665.184	-	390.325
	=	274.9

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $274.9 Mil mean?

ADMA Biologics (ADMA) has a Total Liabilities of $274.9 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ADMA Biologics and its competitors.

Is ADMA Biologics' Total Liabilities too high?

ADMA Biologics' current Total Liabilities is $274.9 Mil. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does ADMA Biologics' Total Liabilities compare to ZYME and NRIX?

ADMA Biologics' Total Liabilities of $274.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ADMA Biologics and its competitors. ADMA Biologics's current Total Liabilities is $274.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ADMA Biologics stock overvalued right now?

Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $17.95, compared to a current price of $8.73 — trading 51.4% below its estimated fair value. The current Total Liabilities is $274.9 Mil. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Total Liabilities is $274.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.73 is trading 51.4% below its estimated GF Value™ of $17.95. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

Total Liabilities: $274.9 Mil
GF Value™: $17.95 vs. price of $8.73 (51.4% below fair value)
GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Industry Healthcare Biotechnology

Comparable Companies ZYME NRIX IOVA HRMY ABCL SRPT RAPP NVAX QURE RXRX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 465 State Route 17, Ramsey, NJ, USA, 07446

Website https://www.admabiologics.com

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

64GF Score

Get the complete analysis for ADMA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.73

Price

$17.95

GF Value

View ADMA Analysis

See Total Liabilities data for all stocks →